Antibodies that define unique Meningococcal B epitopes and vaccine compositions
AssigneesChiron Corporation, Children's Hospital Medical Center of Northern California
InventorsDan M. Granoff, Gregory R. Moe
Life of this patent
Estimating the term…
Abstract
Novel bactericidal antibodies against Neisseria meningitidis serogroup B ("MenB") are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
Claims4
An isolated antibody directed against an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide, wherein said antibody is not autoreactive or minimally autoreactive as determined by measuring the ability of said antibody to react with human neuroblastoma cell line CHP-134, wherein the antibody is produced using an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide-protein conjugate having a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight, wherein the antibody is monoclonal antibody SEAM-2 produced by the hybridoma having ATCC Accession number CRL-12380.
An isolated antibody directed against an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide, wherein said antibody is not autoreactive or minimally autoreactive as determined by measuring the ability of said antibody to react with human neuroblastoma cell line CHP-134, wherein the antibody is produced using an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide-protein conjugate having a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight, wherein the antibody is monoclonal antibody SEAM-3 produced by the hybridoma having ATCC Accession number HB-12170.
An isolated antibody directed against an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide, wherein said antibody is not autoreactive or minimally autoreactive as determined by measuring the ability of said antibody to react with human neuroblastoma cell line CHP-134, wherein the antibody is produced using an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide-protein conjugate having a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight, wherein the antibody is monoclonal antibody SEAM-12 produced by the hybridoma having ATCC Accession number CRL-12381.
An isolated antibody directed against an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide, wherein said antibody is not autoreactive or minimally autoreactive as determined by measuring the ability of said antibody to react with human neuroblastoma cell line CHP-134, wherein the antibody is produced using an N-propionylated Neisseria meningitidis serogroup B capsular polysaccharide-protein conjugate having a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight, wherein the antibody is monoclonal antibody SEAM-18 produced by the hybridoma having ATCC Accession number HB-12169.
Dependencies are inferred from the claim text.